Voxzogo Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to improved genetic testing for achondroplasia, clinical validation of CNP pathway modulation, rising awareness of skeletal dysplasias, expansion of pediatric specialty care, regulatory approvals for rare disease biologics.

The growth in the forecast period can be attributed to increasing demand for disease-modifying therapies, expansion of newborn genetic screening programs, rising investments in rare pediatric drug development, growing focus on personalized medicine, advancements in biologic drug delivery technologies. Major trends in the forecast period include increasing adoption of targeted genetic disorder therapies, rising use of peptide-based growth modulators, growing focus on early intervention for rare diseases, expansion of personalized pediatric treatments, enhanced emphasis on long-term growth outcomes.

The growing focus and investment in rare diseases is expected to drive the growth of the Voxzogo market. Rare diseases are medical conditions affecting a small portion of the population, typically fewer than 200,000 people in a given country. Increased attention and investment in rare diseases are fueled by advances in genetic research, opportunities for innovative therapies, and recognition of the unmet medical needs of affected patients. Such investments support Voxzogo by enabling the development and accessibility of treatments for conditions like achondroplasia, thereby expanding its market presence and addressing critical healthcare gaps. For instance, in February 2024, the Government of Canada invested $20 million to improve health outcomes for children living with rare diseases. Therefore, the growing focus and investment in rare diseases is driving Voxzogo market growth.

The rise of personalized medicine is also expected to propel the Voxzogo market forward. Personalized medicine tailors treatments to an individual’s genetic makeup, lifestyle, and specific health needs. Its growth is driven by advancements in genomics, precision therapeutics, and the ability to target diseases based on a patient’s unique genetic profile. Voxzogo supports personalized medicine by providing a treatment specifically designed for children with achondroplasia, addressing the condition’s distinct genetic and biological characteristics, and improving individual outcomes and quality of life. For example, in February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, a significant increase from six approvals in 2022. This trend highlights how personalized approaches are shaping the growth of the Voxzogo market.

A key trend in the Voxzogo market is the expansion of indications to broaden treatment options for patients with achondroplasia. Expanding indications aims to improve growth and bone health in patients beyond the current approved age groups, including adolescents and potentially adults, as well as other skeletal dysplasias. For instance, in October 2023, BioMarin Pharmaceutical Inc., a US-based biotechnology company, received FDA approval for Voxzogo (vosoritide) to treat children under five years of age with achondroplasia, expanding its prior approval for children aged five and older. The treatment, administered via subcutaneous injections, is designed to increase linear growth in children with open growth plates, with greater potential benefits when initiated at a younger age.

Major companies operating in the voxzogo market are BioMarin Pharmaceutical Inc.

North America was the largest region in the voxzogo market in 2025. The regions covered in the voxzogo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the voxzogo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the voxzogo market by increasing costs of imported biologic manufacturing equipment, peptide synthesis materials, cold-chain storage systems, and clinical distribution logistics. Pediatric specialty care markets in North America and Europe are most affected due to reliance on international biologics supply chains. These tariffs are increasing therapy costs and placing pressure on healthcare reimbursement systems. However, they are also supporting domestic biologics manufacturing expansion, regional supply chain localization, and long-term investment in rare disease drug production capabilities.

The voxzogo market research report is one of a series of new reports that provides voxzogo market statistics, including voxzogo industry global market size, regional shares, competitors with a voxzogo market share, detailed voxzogo market segments, market trends and opportunities, and any further data you may need to thrive in the voxzogo industry. This voxzogo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Voxzogo (vosoritide) is a biologic therapy used to treat achondroplasia, a condition caused by a genetic mutation in the FGFR3 gene. It promotes bone growth by counteracting the effects of FGFR3 and enhancing endochondral ossification at the growth plates through modulation of C-type natriuretic peptide (CNP) activity.

The primary indications for Voxzogo include growth hormone deficiency, Noonan syndrome, achondroplasia, and other growth-related disorders. Growth hormone deficiency (GHD) is a condition in which the pituitary gland produces insufficient growth hormone (GH), affecting normal growth and development. Voxzogo is distributed through hospital pharmacies, retail pharmacies, online pharmacies, and clinics, and is used by pediatric, adult, and geriatric patients.

The voxzogo market consists of sales of injection delivery devices, supportive therapies, genetic testing kits, and growth monitoring devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.